MX2024010608A - Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados. - Google Patents
Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados.Info
- Publication number
- MX2024010608A MX2024010608A MX2024010608A MX2024010608A MX2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- macro
- medium
- substituted heterocycle
- related uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315438P | 2022-03-01 | 2022-03-01 | |
| US202363439477P | 2023-01-17 | 2023-01-17 | |
| PCT/US2023/014275 WO2023167925A1 (en) | 2022-03-01 | 2023-03-01 | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010608A true MX2024010608A (es) | 2024-09-23 |
Family
ID=85772026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010608A MX2024010608A (es) | 2022-03-01 | 2023-03-01 | Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250236629A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486748A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507852A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240157067A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119110802A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023228830A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245204A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002576A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315237A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010608A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400606A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023167925A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| EP4680611A1 (en) | 2023-03-16 | 2026-01-21 | Takeda Pharmaceutical Company Limited | Macrocyclic heterocycle compounds and use thereof |
| JP2026518313A (ja) | 2023-06-01 | 2026-06-04 | ハー・ルンドベック・アクチエゼルスカベット | スピロ大環状オレキシン2受容体アゴニスト |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| US20260144795A1 (en) | 2024-11-27 | 2026-05-28 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| PE20211700A1 (es) | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| KR20260083444A (ko) * | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| CN116635393A (zh) * | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
-
2023
- 2023-03-01 WO PCT/US2023/014275 patent/WO2023167925A1/en not_active Ceased
- 2023-03-01 KR KR1020247032615A patent/KR20240157067A/ko active Pending
- 2023-03-01 EP EP23713207.1A patent/EP4486748A1/en active Pending
- 2023-03-01 IL IL315237A patent/IL315237A/en unknown
- 2023-03-01 TW TW112107384A patent/TW202400606A/zh unknown
- 2023-03-01 JP JP2024551975A patent/JP2025507852A/ja active Pending
- 2023-03-01 MX MX2024010608A patent/MX2024010608A/es unknown
- 2023-03-01 CA CA3245204A patent/CA3245204A1/en active Pending
- 2023-03-01 CN CN202380037293.8A patent/CN119110802A/zh active Pending
- 2023-03-01 AU AU2023228830A patent/AU2023228830A1/en active Pending
-
2024
- 2024-08-28 US US18/817,943 patent/US20250236629A1/en active Pending
- 2024-08-29 CL CL2024002576A patent/CL2024002576A1/es unknown
-
2025
- 2025-04-11 US US19/177,396 patent/US20250289828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240157067A (ko) | 2024-10-31 |
| TW202400606A (zh) | 2024-01-01 |
| US20250289828A1 (en) | 2025-09-18 |
| JP2025507852A (ja) | 2025-03-21 |
| CL2024002576A1 (es) | 2025-01-10 |
| EP4486748A1 (en) | 2025-01-08 |
| AU2023228830A1 (en) | 2024-09-12 |
| CA3245204A1 (en) | 2023-09-07 |
| CN119110802A (zh) | 2024-12-10 |
| US20250236629A1 (en) | 2025-07-24 |
| WO2023167925A1 (en) | 2023-09-07 |
| IL315237A (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022051596A8 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| CL2024002576A1 (es) | Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados | |
| EP3610874A1 (en) | Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof | |
| BRPI0417687A (pt) | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade | |
| WO2012045883A1 (en) | Cyclopropylamine inhibitors of oxidases | |
| BR112020010429A2 (pt) | uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor | |
| NO20075353L (no) | Forbindelser, isomerer og farmasoytisk akseptable salter derav, som vanilloidreseptorantagonister, og farmasoytiske preparater inneholdende slike | |
| KR20170108887A (ko) | NamPT 억제용 신규 화합물 및 이를 포함하는 조성물 | |
| BR112019016248A2 (pt) | piridinas substituídas com hidrocarbilssulfonila e uso das mesmas no tratamento de câncer | |
| BR112019016233A2 (pt) | piridinas substituídas com heterociclilsulfonila e uso das mesmas no tratamento de câncer | |
| JP7600131B2 (ja) | 神経系疾患の予防または治療用薬学的組成物 | |
| MX2025001865A (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| CZ111897A3 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
| CA2792913A1 (en) | Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| EP3836912B1 (en) | Combinations of substituted benzamides and 5-asa agents | |
| EP2668159A1 (en) | 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives | |
| EP4061371B1 (en) | Masitinib for the treatment of sickle cell disease | |
| CA3201259A1 (en) | Masitinib for the treatment of alzheimer's disease | |
| MX2023004623A (es) | Moduladores de la via integrada de respuesta al estres. | |
| WO2024151519A3 (en) | Pparg modulators | |
| MX2024013549A (es) | Heterociclos novedosos, métodos de preparación y usos de los mismos | |
| BR112022008265A2 (pt) | Composições farmacêuticas contendo diácido de oligossacarídeo de alginato | |
| HK40050156B (en) | Co-crystal of sorafenib derivatives and process for preparation thereof | |
| WO2025178571A1 (en) | Anti-non-tuberculous mycobacteria inhibitors | |
| EP4351574A1 (en) | Inhibitors of ttbk1 |